Blind Patients See Again! Here’s How

Close-up view of a human eye showcasing the iris and eyelashes

A tiny wireless chip smaller than a pencil eraser, surgically placed beneath the retina, has restored the ability to read in patients who lost their central vision to macular degeneration—a disease that robs more than five million people worldwide of their sight.

Story Snapshot

The PRIMA wireless retinal implant enabled 81% of trial participants to gain significant vision improvement, with 84% reading letters and words at home after 15 years of blindness.
Unlike previous devices limited to peripheral vision, this 2×2 millimeter subretinal chip targets central vision loss caused by geographic atrophy in age-related macular degeneration.
The device converts near-infrared light from specialized glasses into electrical signals that bypass dead photoreceptors, stimulating surviving retinal cells with 378 photovoltaic pixels.
Science Corporation filed for FDA and European regulatory approval in early 2026 following publication of landmark trial results in The New England Journal of Medicine.

When Prior Technology Failed Macular Degeneration Patients

Retinal prostheses emerged in the 2010s with limited success. The Argus II implant, approved in 2013, offered glimpses of light and movement for retinitis pigmentosa patients but proved useless for macular degeneration sufferers. That device stimulated the wrong retinal layer and provided only peripheral awareness—no central vision for reading or recognizing faces. Discontinued in 2020 due to cost and safety concerns, it left a massive unmet need. Geographic atrophy from age-related macular degeneration destroys the central macula, creating blind spots where critical vision once existed. Over five million people live with this progressive blindness, watching their independence erode as reading, driving, and facial recognition become impossible.

How a Wireless Chip Restores What Medicine Cannot

Daniel Palanker at Stanford University spent 15 years developing an entirely different approach. His PRIMA system places a wireless photovoltaic chip just two millimeters square under the retina during vitrectomy surgery. Unlike the Argus II’s bulky wired design requiring skull fixation, PRIMA has no external cables or hardware protruding from the eye. Patients wear specialized glasses equipped with a camera and near-infrared projector. The glasses capture the visual scene, process it, and beam amplified near-infrared light onto the subretinal chip. Its 378 microscopic pixels convert that light into electrical pulses, stimulating bipolar cells—the retinal layer immediately after photoreceptors—to send signals through surviving optic nerve pathways to the brain.

Trial Results That Exceeded Expectations

The multicenter trial enrolled 38 patients across five countries between 2023 and 2025, all legally blind with central vision worse than 1.2 logMAR. At 12 months post-implant, 32 participants completed assessments. Twenty-six patients—81%—gained at least 0.2 logMAR improvement in visual acuity, an average gain of 0.51 logMAR equivalent to reading approximately five additional lines on an eye chart. Even more striking, 27 patients—84%—reported reading letters or words independently at home using the device. José-Alain Sahel, senior author and UPMC ophthalmology chair, said researchers could not have imagined such outcomes when Palanker began this work. The glasses offer zoom magnification up to 12-times, compensating for the chip’s relatively low pixel count and enabling functional reading despite the device’s technical limitations.

Safety Profile Shows Manageable Surgical Risks

Adverse events occurred predominantly during and immediately after surgery, consistent with vitrectomy procedures. Three patients developed macular holes that resolved with treatment. Ninety-five percent of complications cleared within two months. Crucially, no patients lost peripheral vision, and the implant caused no damage to surrounding retinal structures. The atrophic area increased slightly post-surgery, an expected progression of the underlying disease rather than implant-related harm. Patient satisfaction reached 69% at medium-high levels, though behavioral vision impairment indices showed no change at 12 months, suggesting longer adaptation periods may enhance subjective outcomes. The safety data supported Science Corporation’s regulatory filings in early 2026 for FDA and European approval.

Wireless retinal implant helps blind patients see again: https://t.co/L1hdSbRWCm

— Ken Gusler (@kgusler) March 3, 2026

What This Means for Millions Facing Blindness

This breakthrough marks the first scalable therapy enabling central vision restoration in late-stage macular degeneration. Previous interventions—anti-VEGF injections, laser treatments—slow progression but cannot reverse photoreceptor death. Gene therapies remain experimental and inapplicable once cells die. PRIMA offers hope when medicine reaches its limit. The technology’s wireless design and subretinal placement represent fundamental advances over cortical implants like Orion, which stimulate the brain’s visual cortex but require invasive neurosurgery. Economic barriers loom large; Argus II cost $150,000, likely setting a floor for PRIMA’s price. Access will depend on insurance coverage and post-approval manufacturing scale. For elderly patients losing independence to AMD, the ability to read medication labels, recognize loved ones, and navigate without constant assistance justifies significant investment. UPMC researchers are exploring applications beyond legal blindness thresholds, potentially expanding the candidate pool.